zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
methylthioninium chloride proveblue
provepharm sas - metiltioniniu - methemoglobinemie - toate celelalte produse terapeutice - tratamentul simptomatic acut al methemoglobinemiei induse de medicamente și produse chimice. methylthioninium chloride proveblue este indicat la adulți, copii și adolescenți (cu vârsta cuprinsă între 0 și 17 ani).
fatrovax rhd
fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - produsele imunologice pentru leporide - iepuri - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.
epirubicin hydrochloride 2 mg/ml soluţie injectabilă/perfuzabilă
accord healthcare limited - epirubicinum - soluţie injectabilă/perfuzabilă - 2 mg/ml
irinotecan hydrochloride 20 mg ml 20 mg/ml concentrat pentru soluţie perfuzabilă
seacross pharmaceuticals limited - irinotecanum - concentrat pentru soluţie perfuzabilă - 20 mg/ml
irinotecan hydrochloride 20 mg ml 20 mg/ml concentrat pentru soluţie perfuzabilă
seacross pharmaceuticals limited - irinotecanum - concentrat pentru soluţie perfuzabilă - 20 mg/ml
irinotecan hydrochloride 20 mg ml 20 mg/ml concentrat pentru soluţie perfuzabilă
seacross pharmaceuticals limited - irinotecanum - concentrat pentru soluţie perfuzabilă - 20 mg/ml
bendamustine hydrochloride 2 5 mg ml 25 mg pulbere pentru concentrat pentru soluţie perfuzabilă
seacross pharmaceuticals limited - bendamustinum - pulbere pentru concentrat pentru soluţie perfuzabilă - 25 mg
bendamustine hydrochloride 2 5 mg ml 100 mg pulbere pentru concentrat pentru soluţie perfuzabilă
seacross pharmaceuticals limited - bendamustinum - pulbere pentru concentrat pentru soluţie perfuzabilă - 100 mg
clindamicina noridem 150 mg/ml
demo s.a. pharmaceutical industry - grecia - clindamycinum - sol inj./perf. - 150mg/ml - macrolide, lincosamide si streptogramine lincosamide